Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer
Chen Wu, Danlei Yu, Shi‐Yong Sun, Feng Li
Topics & Concepts
OsimertinibSelumetinibCancer researchT790Mnon-small cell lung cancer (NSCLC)PEG ratioMedicineMAPK/ERK pathwayLung cancerKinaseCancerChemistryEpidermal growth factor receptorGefitinibErlotinibOncologyA549 cellMEK inhibitorInternal medicineBiochemistryEconomicsFinanceLung Cancer Treatments and MutationsCancer therapeutics and mechanismsLung Cancer Research Studies